About 15 years ago, while riding on a shuttle bus at the annual American Academy of Dermatology meeting, I overheard two elderly dermatologists discussing the state of dermatology, as they perceived it. One gentleman commented that he had not seen a single advance to rival the advent of tetracycline for acne, and that most of the new treatments did not work very well. At the time, I remember thinking that these practitioners were out of touch with all of the hot new therapies for skin disorders. Since that time, as I have been bombarded by myriad new and supposedly revolutionary "advances," I, too, am beginning to question whether we should equate the concept of "newness"
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.